SAN FRANCISCO (AFX) -- Bristol-Myers Squibb Co. after Friday's closing bell said the Food and Drug Administration has approved a supplemental biologics license application for the licensure of Lonza Biologics Inc., a third-party manufacturing facility. The facility will support increased production capacity for Orencia, enabling the company to meet long-term demand, Bristol-Myers said. The FDA approved Orencia for the treatment of rheumatoid arthritis in December. This story was supplied by MarketWatch. For further information see www.marketwatch.com.